

Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

<https://marketpublishers.com/r/C45421530B4EN.html>

Date: November 2012

Pages: 64

Price: US\$ 392.00 (Single User License)

ID: C45421530B4EN

Abstracts

The present Competitive Intelligence Report about VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of November 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Novartis. The full length therapeutic antibody Avastin recorded sales of US\$ 5.6 bln in the year 2011 and is mainly being used for treatment of colorectal, renal cell and non-small cell lung cancer (EU and US) as well as of breast cancer (EU) and glioblastoma (US). The humanized antibody fragment Lucentis marketed by Novartis and Roche/Genentech (USA) generated 2011 sales of US\$ 3.67 bln. Approved indications of Lucentis include wet age-related macular degeneration (AMD), diabetic macular edema (DME) and Macular edema following retinal vein occlusion (RVO).

The next generation of anti-VEGF antibodies is lead by the fusion protein aflibercept with recent first approvals in oncology and ophthalmology and a number of other improved molecules including antibodies targeting the receptors of VEGF. Bispecific antibodies targeting VEGF and a second angiogenic target are strongly emerging, but still in earlier phases.

Patents covering Avastin and Lucentis are going to expire in the US and EU over the next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and the pipeline has at least further ten biosimilars in preparation for further development.

A similar pattern of development activities can be seen for ranibizumab: next generation, improved molecules, delivery solutions, extension of indications and biosimilar molecules.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

1. BEVACIZUMAB BIOSIMILARS AND BIOSUPERIORS

Marketed VEGF Antibody: Avastin Pipeline

Next Generation Avastin Pipeline

Anti-VEGF Antibody Pipeline

Anti-VEGF-R Antibody Pipeline

Bispecific Anti-VEGF Pipeline

Avastin Biosimilar Pipeline

2. RANIBIZUMAB BIOSIMILARS AND BIOSUPERIORS

Marketed VEGF Antibody: Lucentis Pipeline

Next Generation Lucentis Pipeline

Lucentis Biosimilar Pipeline

3. CORPORATE VEGF/-R ANTIBODIES R&D PIPELINES

I would like to order

Product name: Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

Product link: <https://marketpublishers.com/r/C45421530B4EN.html>

Price: US\$ 392.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C45421530B4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

